<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-358
Date of Submission: 2024-10-01

This report was submitted by a Physician from Miller, Prince and Lam Medical Center concerning patient ANON-PX-8767. The subject is an adult other with a significant medical history including coronary artery disease, hypertension, seasonal allergies, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin administered via the Oral route at a dosage of 473mg, initiated on 2024-07-26 for Thromboembolism prevention and discontinued on 2024-09-22.

On approximately 2024-08-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Anaphylaxis. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed network and advised local. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: May carry meet. Court eat available sound measure.</data>
report_id: ADR-2024-358
report_date: '2024-10-01'
patient_details:
  patient_id: ANON-PX-8767
  gender: Other
  relevant_history:
  - coronary artery disease
  - hypertension
  - seasonal allergies
  - asthma
suspected_drugs:
- drug_name: Warfarin
  dosage: 473mg
  route_of_administration: Oral
  start_date: '2024-07-26'
  indication_for_use: Thromboembolism prevention
  end_date: '2024-09-22'
adverse_reactions:
- symptom_name: Pruritus
  onset_date: '2024-08-11'
  severity: Mild
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed network and advised local.
- symptom_name: Anaphylaxis
  onset_date: '2024-08-11'
  severity: Mild
  outcome: Fatal
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
reporting_facility: Miller, Prince and Lam Medical Center
reporter_type: Physician
notes: May carry meet. Court eat available sound measure.
